<DOC>
	<DOCNO>NCT02718378</DOCNO>
	<brief_summary>The current study design phase Ib multiple dose study evaluate safety , tolerability , pharmacokinetics pharmacodynamics E4 healthy men daily oral administration 28 day .</brief_summary>
	<brief_title>Evaluation Safety Efficacy Estetrol Healthy Men</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male , age 40 70 year ( inclusive ) ; Good physical mental health judge Investigator determine medical history , physical examination ( include prostate palpation ) , clinical laboratory , vital sign ECG record ; Body mass index ≥ 18.5 ≤ 30.0 kg/m2 ; Normal prostatespecific antigen ( PSA ) value ( &lt; 3.0 ng/mL ) ; Nonvasectomized men must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study medication . Men vasectomize less 4 month prior study start must follow restriction nonvasectomized men ; Men must agree donate sperm first dose 90 day last dose ; Ability communicate well Investigator comply requirement entire study ; Willing give informed consent write . Any clinically significant abnormality follow review medical history , laboratory result , physical examination ECG screen judged Investigator ; Conditions disorder might affect absorption , distribution , metabolism excretion study drug ; Previous use steroid within : 8 week oral preparation 4 week transdermal preparation Any time injection ; Contraindications steroid estetrol ; Prostate hyperplasia micturition problem suggest presence prostate hyperplasia ; Presence active acute chronic infection , include syphilis , HIV viral hepatitis B and/or C ( previously treat ) ; Treatment major psychiatric disorder previous 12 month use antidepressant medication screening ; Hypersensitivity active substance excipients investigational product placebo therapy ; Use probiotic ( present dairy product , fortify food etc . ) 3 month screen clinical study ; Use one follow medication : Antihypertensive drug Present use use within 30 day start study drug follow drug : aprepitant , bosentan , armodafinil , phenytoin , barbiturate , primidone , carbamazepine , oxcarbazepine , glucocorticoid , topiramate , felbamate , rifampicin , clobazamechinacea ; vemurafenib , nonnucleoside reverse transcriptase inhibitor , griseofulvin , ketoconazole , herbal remedy contain Hypericum perforatum Any medication ( include overthecounter product ) within 14 day first dose except occasional nonsteroidal antiinflammatory drug ( NSAIDs ; e.g . ibuprofen ) ; paracetamol permit Use antibiotic ; Administration investigational drug within 3 month first dose ; Loss 400 mL blood 3 month screen , e.g . blood donor , intention donate blood 3 month complete study ; Subjects history ( within 12 month ) alcohol drug abuse positive result screening , test : alcohol intake drug abuse ; Currently smoke smoke within last 6 month screen .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>randomize</keyword>
</DOC>